{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T23:24:19Z","timestamp":1793316259924,"version":"4.5.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T00:00:00Z","timestamp":1722211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virchows Arch"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s00428-024-03874-w","type":"journal-article","created":{"date-parts":[[2024,7,29]],"date-time":"2024-07-29T12:57:37Z","timestamp":1722257857000},"page":"707-719","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Human epidermal growth factor 2 (HER2) amplification in uterine serous carcinoma: an analysis of prognosis and immune microenvironment"],"prefix":"10.1007","volume":"486","author":[{"given":"Ying","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiyi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7309-1116","authenticated-orcid":false,"given":"Bingjian","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,29]]},"reference":[{"key":"3874_CR1","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1038\/sj.bjc.6603012","volume":"94","author":"CA Hamilton","year":"2006","unstructured":"Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, Powell MA, Hendrickson MR, Kapp DS, Chan JK (2006) Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer 94:642\u2013646","journal-title":"Br J Cancer"},{"key":"3874_CR2","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.ygyno.2018.02.022","volume":"149","author":"L Tortorella","year":"2018","unstructured":"Tortorella L, Langstraat CL, Weaver AL, McGree ME, Bakkum-Gamez JN, Dowdy SC, Cliby WA, Keeney GL, Sherman ME, Weroha SJ, Mariani A, Podratz KC (2018) Uterine serous carcinoma: reassessing effectiveness of platinum-based adjuvant therapy. Gynecol Oncol 149:291\u2013296","journal-title":"Gynecol Oncol"},{"key":"3874_CR3","first-page":"293","volume":"21","author":"G Menderes","year":"2016","unstructured":"Menderes G, Clark M, Santin AD (2016) Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer. Discov Med 21:293\u2013303","journal-title":"Discov Med"},{"key":"3874_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ygyno.2020.09.003","volume":"159","author":"EC Rossi","year":"2020","unstructured":"Rossi EC (2020) Identifying the worst of the worst: HER2 positive early stage uterine papillary serous carcinoma. Gynecol Oncol 159:1\u20132","journal-title":"Gynecol Oncol"},{"key":"3874_CR5","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ygyno.2020.07.016","volume":"159","author":"BK Erickson","year":"2020","unstructured":"Erickson BK, Najjar O, Damast S, Blakaj A, Tymon-Rosario J, Shahi M, Santin A, Klein M, Dolan M, Cimino-Mathews A, Buza N, Ferriss JS, Stone RL, Khalifa M, Fader AN (2020) Human epidermal growth factor 2 (HER2) in early stage uterine serous carcinoma: a multi-institutional cohort study. Gynecol Oncol 159:17\u201322","journal-title":"Gynecol Oncol"},{"key":"3874_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.drup.2017.02.002","volume":"30","author":"JD Twomey","year":"2017","unstructured":"Twomey JD, Brahme NN, Zhang B (2017) Drug-biomarker co-development in oncology - 20 years and counting. Drug Resist Updat 30:48\u201362","journal-title":"Drug Resist Updat"},{"key":"3874_CR7","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/j.1365-2559.2009.03464.x","volume":"56","author":"M Xu","year":"2010","unstructured":"Xu M, Schwartz P, Rutherford T, Azodi M, Santin A, Silasi D, Martel M, Hui P (2010) HER-2\/neu receptor gene status in endometrial carcinomas: a tissue microarray study. Histopathology 56:269\u2013273","journal-title":"Histopathology"},{"key":"3874_CR8","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2017.76.5966","volume":"36","author":"AN Fader","year":"2018","unstructured":"Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers SK, Secord AA, Havrilesky L, O\u2019Malley DM, Backes F, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi KS, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD (2018) Randomized phase II trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-trastuzumab in uterine serous carcinomas that overexpress human epidermal growth factor receptor 2\/Neu. J Clin Oncol 36:2044\u20132051","journal-title":"J Clin Oncol"},{"key":"3874_CR9","doi-asserted-by":"publisher","first-page":"3928","DOI":"10.1158\/1078-0432.CCR-20-0953","volume":"26","author":"AN Fader","year":"2020","unstructured":"Fader AN, Roque DM, Siegel E, Buza N, Hui P, Abdelghany O, Chambers S, Secord AA, Havrilesky L, O\u2019Malley DM, Backes FJ, Nevadunsky N, Edraki B, Pikaart D, Lowery W, ElSahwi K, Celano P, Bellone S, Azodi M, Litkouhi B, Ratner E, Silasi DA, Schwartz PE, Santin AD (2020) Randomized phase II trial of carboplatin-paclitaxel compared with carboplatin-paclitaxel-trastuzumab in advanced (stage III-IV) or recurrent uterine serous carcinomas that overexpress Her2\/Neu (NCT01367002): updated overall survival analysis. Clin Cancer Res 26:3928\u20133935","journal-title":"Clin Cancer Res"},{"key":"3874_CR10","unstructured":"National Comprehensive Cancer Network. Uterine Neoplasms (Version 4.2019). https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/uterine.pdf. Accessed Oct 2019"},{"key":"3874_CR11","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1097\/PAS.0000000000001870","volume":"46","author":"TM Jenkins","year":"2022","unstructured":"Jenkins TM, Cantrell LA, Stoler MH, Mills AM (2022) HER2 overexpression and amplification in uterine carcinosarcomas with serous morphology. Am J Surg Pathol 46:435\u2013442","journal-title":"Am J Surg Pathol"},{"key":"3874_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1097\/PGP.0000000000000711","volume":"40","author":"N Buza","year":"2021","unstructured":"Buza N (2021) HER2 testing and reporting in endometrial serous carcinoma: practical recommendations for HER2 immunohistochemistry and fluorescent in situ hybridization: proceedings of the ISGyP Companion Society Session at the 2020 USCAP Annual Meeting. Int J Gynecol Pathol 40:17\u201323","journal-title":"Int J Gynecol Pathol"},{"key":"3874_CR13","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/gcc.22113","volume":"52","author":"N Buza","year":"2013","unstructured":"Buza N, Hui P (2013) Marked heterogeneity of HER2\/NEU gene amplification in endometrial serous carcinoma. Genes Chromosomes Cancer 52:1178\u20131186","journal-title":"Genes Chromosomes Cancer"},{"key":"3874_CR14","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1038\/modpathol.2013.113","volume":"26","author":"N Buza","year":"2013","unstructured":"Buza N, English DP, Santin AD, Hui P (2013) Toward standard HER2 testing of endometrial serous carcinoma: 4-year experience at a large academic center and recommendations for clinical practice. Mod Pathol 26:1605\u20131612","journal-title":"Mod Pathol"},{"key":"3874_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","volume":"53","author":"EC Paver","year":"2021","unstructured":"Paver EC, Cooper WA, Colebatch AJ, Ferguson PM, Hill SK, Lum T, Shin JS, O\u2019Toole S, Anderson L, Scolyer RA, Gupta R (2021) Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. Pathology 53:141\u2013156","journal-title":"Pathology"},{"key":"3874_CR16","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1097\/PAS.0000000000001682","volume":"45","author":"N Banet","year":"2021","unstructured":"Banet N, Shahi M, Batista D, Yonescu R, Tanner EJ, Fader AN, Cimino-Mathews A (2021) HER-2 amplification in uterine serous carcinoma and serous endometrial intraepithelial carcinoma. Am J Surg Pathol 45:708\u2013715","journal-title":"Am J Surg Pathol"},{"key":"3874_CR17","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/cncr.21308","volume":"104","author":"AD Santin","year":"2005","unstructured":"Santin AD, Bellone S, Van Stedum S, Bushen W, Palmieri M, Siegel ER, De Las Casas LE, Roman JJ, Burnett A, Pecorelli S (2005) Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer 104:1391\u20131397","journal-title":"Cancer"},{"key":"3874_CR18","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1111\/j.1349-7006.2012.02240.x","volume":"103","author":"S Togami","year":"2012","unstructured":"Togami S, Sasajima Y, Oi T, Ishikawa M, Onda T, Ikeda S, Kato T, Tsuda H, Kasamatsu T (2012) Clinicopathological and prognostic impact of human epidermal growth factor receptor type 2 (HER2) and hormone receptor expression in uterine papillary serous carcinoma. Cancer Sci 103:926\u2013932","journal-title":"Cancer Sci"},{"key":"3874_CR19","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1200\/JCO.2005.03.4827","volume":"24","author":"C Morrison","year":"2006","unstructured":"Morrison C, Zanagnolo V, Ramirez N, Cohn DE, Kelbick N, Copeland L, Maxwell GL, Fowler JM (2006) HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24:2376\u20132385","journal-title":"J Clin Oncol"},{"key":"3874_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2007.09.007","volume":"108","author":"TA Grushko","year":"2008","unstructured":"Grushko TA, Filiaci VL, Mundt AJ, Ridderstr\u00e5le K, Olopade OI, Fleming GF (2008) An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 108:3\u20139","journal-title":"Gynecol Oncol"},{"key":"3874_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ygyno.2022.09.006","volume":"167","author":"TR Klc","year":"2022","unstructured":"Klc TR, Wu S, Wilhite AM, Jones NL, Powell MA, Olawaiye A, Girda E, Brown J, Puechl A, Ali-Fehmi R, Winer IS, Herzog TJ, Korn WM, Erickson BK (2022) HER2 in uterine serous carcinoma: testing platforms and implications for targeted therapy. Gynecol Oncol 167:289\u2013294","journal-title":"Gynecol Oncol"},{"key":"3874_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2020.100561","volume":"32","author":"MR Quddus","year":"2020","unstructured":"Quddus MR, Hansen K, Tantravahi U, Sung CJ (2020) Human epidermal growth factor receptor 2 (Her2) testing for uterine serous carcinoma: report of scenarios of unusual overexpression. Gynecol Oncol Rep 32:100561","journal-title":"Gynecol Oncol Rep"},{"key":"3874_CR23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/PGP.0000000000000690","volume":"40","author":"D Rottmann","year":"2021","unstructured":"Rottmann D, Assem H, Matsumoto N, Wong S, Hui P, Buza N (2021) Does specimen type have an impact on HER2 status in endometrial serous carcinoma? Discordant HER2 status of paired endometrial biopsy and hysterectomy specimens in the presence of frequent intratumoral heterogeneity. Int J Gynecol Pathol 40:263\u2013271","journal-title":"Int J Gynecol Pathol"},{"key":"3874_CR24","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, Bilous M, Ellis IO, Fitzgibbons P, Hanna W, Jenkins RB, Press MF, Spears PA, Vance GH, Viale G, McShane LM, Dowsett M (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline focused update. J Clin Oncol 36:2105\u20132122","journal-title":"J Clin Oncol"},{"key":"3874_CR25","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1007\/s00535-018-1464-0","volume":"53","author":"T Wakatsuki","year":"2018","unstructured":"Wakatsuki T, Yamamoto N, Sano T, Chin K, Kawachi H, Takahari D, Ogura M, Ichimura T, Nakayama I, Osumi H, Matsushima T, Suenaga M, Shinozaki E, Hiki N, Ishikawa Y, Yamaguchi K (2018) Clinical impact of intratumoral HER2 heterogeneity on trastuzumab efficacy in patients with HER2-positive gastric cancer. J Gastroenterol 53:1186\u20131195","journal-title":"J Gastroenterol"},{"key":"3874_CR26","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/ajcp\/aqz010","volume":"152","author":"KE Muller","year":"2019","unstructured":"Muller KE, Marotti JD, Tafe LJ (2019) Pathologic features and clinical implications of breast cancer with HER2 intratumoral genetic heterogeneity. Am J Clin Pathol 152:7\u201316","journal-title":"Am J Clin Pathol"},{"key":"3874_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.ygyno.2005.03.041","volume":"98","author":"AD Santin","year":"2005","unstructured":"Santin AD, Bellone S, Van Stedum S, Bushen W, De Las Casas LE, Korourian S, Tian E, Roman JJ, Burnett A, Pecorelli S (2005) Determination of HER2\/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol 98:24\u201330","journal-title":"Gynecol Oncol"},{"key":"3874_CR28","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi S, Jacot W, Yamashita T, Sohn J, Vidal M, Tokunaga E, Tsurutani J, Ueno NT, Prat A, Chae YS, Lee KS, Niikura N, Park YH, Xu B, Wang X, Gil-Gil M, Li W, Pierga JY, Im SA, Moore HCF, Rugo HS, Yerushalmi R, Zagouri F, Gombos A, Kim SB, Liu Q, Luo T, Saura C, Schmid P, Sun T, Gambhire D, Yung L, Wang Y, Singh J, Vitazka P, Meinhardt G, Harbeck N, Cameron DA, Investigators DE-BT (2022) Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med 387:9\u201320","journal-title":"N Engl J Med"},{"key":"3874_CR29","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1158\/1535-7163.MCT-16-0163","volume":"15","author":"J Black","year":"2016","unstructured":"Black J, Menderes G, Bellone S, Schwab CL, Bonazzoli E, Ferrari F, Predolini F, De Haydu C, Cocco E, Buza N, Hui P, Wong S, Lopez S, Ratner E, Silasi DA, Azodi M, Litkouhi B, Schwartz PE, Goedings P, Beusker PH, van der Lee MM, Timmers CM, Dokter WH, Santin AD (2016) SYD985, a novel duocarmycin-based HER2-targeting antibody-drug conjugate, shows antitumor activity in uterine serous carcinoma with HER2\/Neu expression. Mol Cancer Ther 15:1900\u20131909","journal-title":"Mol Cancer Ther"},{"key":"3874_CR30","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S1470-2045(19)30328-6","volume":"20","author":"U Banerji","year":"2019","unstructured":"Banerji U, van Herpen CML, Saura C, Thistlethwaite F, Lord S, Moreno V, Macpherson IR, Boni V, Rolfo C, de Vries EGE, Rottey S, Geenen J, Eskens F, Gil-Martin M, Mommers EC, Koper NP, Aftimos P (2019) Trastuzumab duocarmazine in locally advanced and metastatic solid tumours and HER2-expressing breast cancer: a phase 1 dose-escalation and dose-expansion study. Lancet Oncol 20:1124\u20131135","journal-title":"Lancet Oncol"},{"key":"3874_CR31","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.ygyno.2023.03.008","volume":"172","author":"SF Bruce","year":"2023","unstructured":"Bruce SF, Wu S, Ribeiro JR, Farrell A, Oberley MJ, Winer I, Erickson BK, Klc T, Jones NL, Thaker PH, Powell MA (2023) HER2+ endometrioid endometrial cancer possesses distinct molecular and immunologic features associated with a more active immune microenvironment and worse prognosis. Gynecol Oncol 172:98\u2013105","journal-title":"Gynecol Oncol"},{"issue":"1","key":"3874_CR32","doi-asserted-by":"publisher","first-page":"44","DOI":"10.3390\/cancers13010044","volume":"13","author":"L Vermij","year":"2020","unstructured":"Vermij L, Horeweg N, Leon-Castillo A, Rutten TA, Mileshkin LR, Mackay HJ, Leary A, Powell ME, Singh N, Crosbie EJ, Smit VTHBM, Creutzberg CL, Bosse T (2020) HER2 status in high-risk endometrial cancers (PORTEC-3): relationship with histotype, molecular classification, and clinical outcomes. Cancers (Basel) 13(1):44","journal-title":"Cancers (Basel)"},{"key":"3874_CR33","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ygyno.2017.03.022","volume":"146","author":"R Salani","year":"2017","unstructured":"Salani R, Khanna N, Frimer M, Bristow RE, Chen LM (2017) An update on post-treatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncology (SGO) recommendations. Gynecol Oncol 146:3\u201310","journal-title":"Gynecol Oncol"},{"key":"3874_CR34","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1016\/S1470-2045(19)30020-8","volume":"20","author":"V Makker","year":"2019","unstructured":"Makker V, Rasco D, Vogelzang NJ, Brose MS, Cohn AL, Mier J, Di Simone C, Hyman DM, Stepan DE, Dutcus CE, Schmidt EV, Guo M, Sachdev P, Shumaker R, Aghajanian C, Taylor M (2019) Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet Oncol 20:711\u2013718","journal-title":"Lancet Oncol"},{"issue":"2","key":"3874_CR35","doi-asserted-by":"publisher","first-page":"528","DOI":"10.3390\/cancers15020528","volume":"15","author":"EA Bloom","year":"2023","unstructured":"Bloom EA, Peters PN, Whitaker R, Russell S, Albright B, Cummings S, Timms KM, Slavin T, Probst B, Strickland KC, Previs RA (2023) Association of genomic instability score, tumor mutational burden, and tumor-infiltrating lymphocytes as biomarkers in uterine serous carcinoma. Cancers (Basel) 15(2):528","journal-title":"Cancers (Basel)"},{"key":"3874_CR36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s10549-011-1620-1","volume":"132","author":"SM Mahmoud","year":"2012","unstructured":"Mahmoud SM, Lee AH, Paish EC, Macmillan RD, Ellis IO, Green AR (2012) The prognostic significance of B lymphocytes in invasive carcinoma of the breast. Breast Cancer Res Treat 132:545\u2013553","journal-title":"Breast Cancer Res Treat"},{"key":"3874_CR37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/sj.bjc.6602930","volume":"94","author":"L Arnould","year":"2006","unstructured":"Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, Cabaret V, Fermeaux V, Bertheau P, Garnier J, Jeannin JF, Coudert B (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94:259\u2013267","journal-title":"Br J Cancer"},{"issue":"2","key":"3874_CR38","doi-asserted-by":"publisher","first-page":"R48","DOI":"10.1186\/bcr3148","volume":"14","author":"S Liu","year":"2012","unstructured":"Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO (2012) CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer. Breast Cancer Res 14(2):R48","journal-title":"Breast Cancer Res"},{"issue":"7","key":"3874_CR39","first-page":"1107","volume":"58","author":"K Baker","year":"2011","unstructured":"Baker K, Lachapelle J, Zlobec I, Bismar TA, Terracciano L, Foulkes WD (2011) Prognostic significance of CD8+ T lymphocytes in breast cancer depends upon both oestrogen receptor status and histological grade. Histopathology 58(7):1107\u20131116","journal-title":"Histopathology"},{"issue":"1","key":"3874_CR40","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12282-016-0698-z","volume":"24","author":"S Burugu","year":"2017","unstructured":"Burugu S, Asleh-Aburaya K, Nielsen TO (2017) Immune infiltrates in the breast cancer microenvironment: detection, characterization and clinical implication. Breast Cancer 24(1):3\u201315","journal-title":"Breast Cancer"}],"container-title":["Virchows Archiv"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03874-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00428-024-03874-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00428-024-03874-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T06:20:44Z","timestamp":1745389244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00428-024-03874-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,29]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["3874"],"URL":"https:\/\/doi.org\/10.1007\/s00428-024-03874-w","relation":{},"ISSN":["0945-6317","1432-2307"],"issn-type":[{"value":"0945-6317","type":"print"},{"value":"1432-2307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,29]]},"assertion":[{"value":"2 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted with the approval of the Institutional Review Board of Women\u2019s Hospital, School of Medicine, Zhejiang University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}